Phase 2 N=26 A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Phase 3 N=716 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Brain Neoplasms
Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months
Phase 3 N=560 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Brain Cancer
Primary: Overall Survival (OS) — 13.40; 14.88 Months — p=0.0037
Phase 2 N=64 DC Migration Study for Newly-Diagnosed GBM
Glioblastoma · Astrocytoma, Grade IV · Giant Cell Glioblastoma
Primary: Median Overall Survival — 16; 20; 19 months — p=0.072
Phase 2 N=6 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
GBM · Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab. — 6…
Phase 2 N=90 Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
Brain Cancer
Primary: Time to Cognitive Failure — 7.7; 4.9 months — p=.74
Phase 2 N=68 Bevacizumab Beyond Progression (BBP)
Malignant Glioma · Grade 4 Malignant Glioma · Glioblastoma
Primary: Overall Survival — 17.8 months
Phase 2 N=158 A Study in Recurrent Glioblastoma (GB)
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants
Phase 2 N=124 A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme
Primary: Overall Survival (OS) — 18.3; 16.7 months of survival
Phase 2 N=66 BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
Phase 2 N=10 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Phase 2 N=16 Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
Glioblastoma Multiforme · Glioblastoma - Category
Primary: Overall Survival (OS) — 11.73 months
N/A N=13 Bevacizumab w / Temozolomide PET & Vascular MRI For GBM
Recurrent Glioblastoma
Primary: Number of Patients With a Decrease in Median Tumor SUV — 6 Participants
Phase 2 N=32 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 96.88 percentage of participants
Phase 2 N=40 Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Malignant Neoplasms of Brain
Primary: Humoral and Cellular Immune Response — 3; 0; 7 participants
Phase 2 N=88 Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Number of Phase I Patients Receiving 60mg or 80mg BKM120 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 3 Participants
Phase 2 N=80 Pembrolizumab +/- Bevacizumab for Recurrent GBM
Glioblastoma
Primary: Pembrolizumab Maximum Tolerated Dose (MTD) [Cohort A Safety Lead-In] — 200 mg every 3 weeks
N/A N=20 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Phase 2 N=62 Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Objective Response — 22.5; 19.4; 11.3; 6.5 percentage of participants
Phase 2 N=68 RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
Glioblastoma Multiforme
Primary: Progression-free Survival (PFS) — 11.3 Months
Phase 2 N=65 Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Glioblastoma
Primary: Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery [Cohort 1] — 6; 1; 7; 1 Participants
Phase 1 N=21 Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
Glioblastoma
Primary: Increase of Interferon Gamma Levels — 0 Participants
Phase 2 N=34 A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Glioblastoma
Primary: Dose-limiting Toxicities (DLTs) — 0; 0 Participants
Phase 2 N=154 Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme · Glioblastoma · Malignant Glioma
Primary: Comparison of Overall Survival (OS) Between the Active Treatment Group (Arms 1 and 2) and the Control Group (Arm 3) — 16.9; 16.2; 20.6 months — p=0.196
Phase 2 N=37 BIBF 1120 for Recurrent High-Grade Gliomas
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: 6-Month Progression Free Survival — 0 percentage of participants
Phase 2 N=35 TH-302 in Combination With Bevacizumab for Glioblastoma
Glioblastoma
Primary: Number of Patients With Adverse Events — 35 Participants
Phase 2 N=180 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.6; 21.1 Months
Phase 2 N=35 Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months